impavido
Impavido (Miltefosine) is an antileishmanial used to treat Visceral Leishmaniasis, Cutaneous Leishmaniasis.
Miltefosine · by Knight Theraps
Key facts
- Active ingredient
- Miltefosine
- Drug class
- Antileishmanial
- Form
- Capsule
- Strength
- Miltefosine 50MG
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- Manufacturer
- Knight Theraps
- FDA application
- NDA204684
Drug class
May treat (source: NIH RxClass)
Dosage forms
Capsule
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Impavido treat?
- Impavido (Miltefosine) may be used to treat visceral leishmaniasis, cutaneous leishmaniasis, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- Is there a coupon or discount for Impavido?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Impavido. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Impavido?
- Impavido is marketed by Knight Theraps. You can see Knight Theraps's full profile, rating, and other products on pharmaranks.
- Is Impavido a brand-name or generic drug?
- Impavido is a brand-name product with the active ingredient Miltefosine.
- Is Impavido available over the counter?
- No. Impavido is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Impavido come in?
- Impavido is currently marketed as capsule, per the FDA's National Drug Code Directory.
- What class of drug is Impavido?
- Impavido is classified as antileishmanial, per the FDA's Established Pharmacologic Class.
- Is Impavido FDA-registered?
- Impavido is on record with the U.S. FDA under application number NDA204684. You can verify this on its official FDA label.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about MILTEFOSINE
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 281 reports naming MILTEFOSINE — the active ingredient in Impavido, and the FDA flagged 96% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- nausea41 reports
- vomiting20 reports
- visceral leishmaniasis19 reports
- disease recurrence18 reports
- acanthamoeba infection15 reports
- gastrointestinal disorder15 reports
- renal failure15 reports
- acute kidney injury13 reports
Read these as a signal, not a rate. A report does not mean MILTEFOSINE caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
Compare Impavido head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
impavido
New